Form 8-K - Current report:
SEC Accession No. 0001628280-17-006984
Filing Date
2017-07-10
Accepted
2017-07-10 17:10:04
Documents
4
Period of Report
2017-07-10
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K - TOTECT FDA APPROVAL a8k-totectapproval.htm 8-K 29528
2 EXHIBIT 99.1 - TOTECT FDA APPROVAL pressrelease-totectfdaappr.htm EX-99.1 19495
3 clinigena03.jpg GRAPHIC 12175
4 cumberlanda11.jpg GRAPHIC 96793
  Complete submission text file 0001628280-17-006984.txt   200296
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 17958449
SIC: 2834 Pharmaceutical Preparations